Survival outcome differences based on treatments used and knowledge of the primary tumour site for patients with cancer of unknown and known primary in Ontario.

Autor: Kim, C. S.¹, Hannouf, M. B.¹, Sarma, S.¹, Rodrigues, G. B.², Rogan, P. K.³, Mahmud, S. M.⁴, Winquist, E.⁵, Brackstone, M.⁶, Zaric, G. S.^1,7 gzaric@ivey.uwo.ca

Publikováno v: Current Oncology. Oct2018, Vol. 25 Issue 5, p307-316. 10p. 5 Charts, 3 Graphs.

The clinical significance of occult gynecologic primary tumours in metastatic cancer.

Autor: Hannouf, M. B.^1,2 mbassamh@uwo.ca, Winquist, E.³, Mahmud, S. M.⁴, Brackstone, M.^3,5, Sarma, S.¹, Rodrigues, G.^1,6, Rogan, P. K.^3,7, Hoch, J. S.^8,9,10, Zaric, G. S.^1,2

Publikováno v: Current Oncology. Oct2017, Vol. 24 Issue 5, pe368-e378. 11p. 4 Charts, 1 Graph.

Real-world treatment patterns, clinical outcomes, and health care resource utilization in advanced unresectable hepatocellular carcinoma.

Autor: O'Sullivan DE; Department of Oncology, University of Calgary, Calgary, Alberta, Canada.; Oncology Outcomes Initiative, University of Calgary, Calgary, Alberta, Canada., Boyne DJ; Department of Oncology, University of Calgary, Calgary, Alberta, Canada.; Oncology Outcomes Initiative, University of Calgary, Calgary, Alberta, Canada., Syed IA; AstraZeneca Canada, Mississauga, Ontario, Canada., Shephard C; AstraZeneca Canada, Mississauga, Ontario, Canada., Clouthier DL; AstraZeneca Canada, Mississauga, Ontario, Canada., Yoshida EM; Canadian Liver Foundation, Markham, Ontario, Canada.; Division of Gastroenterology, University of British Columbia, Vancouver, British Columbia, Canada., Spratlin JL; Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada.; Department of Oncology, University of Alberta, Edmonton, Alberta, Canada., Batra A; Department of Oncology, University of Calgary, Calgary, Alberta, Canada., Rigo R; Department of Oncology, University of Calgary, Calgary, Alberta, Canada., Hannouf M; Department of Oncology, University of Calgary, Calgary, Alberta, Canada., Yang Hu X; Department of Oncology, University of Calgary, Calgary, Alberta, Canada., N Jarada T; Department of Oncology, University of Calgary, Calgary, Alberta, Canada.; Oncology Outcomes Initiative, University of Calgary, Calgary, Alberta, Canada., Brenner DR; Department of Oncology, University of Calgary, Calgary, Alberta, Canada.; Oncology Outcomes Initiative, University of Calgary, Calgary, Alberta, Canada., Cheung WY; Department of Oncology, University of Calgary, Calgary, Alberta, Canada.; Oncology Outcomes Initiative, University of Calgary, Calgary, Alberta, Canada.

Publikováno v: Canadian liver journal [Can Liver J] 2022 Nov 07; Vol. 5 (4), pp. 476-492. Date of Electronic Publication: 2022 Nov 07 (Print Publication: 2022).

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Four Cycles of Docetaxel-Cyclophosphamide versus Anthracycline-Taxane as Adjuvant Chemotherapy for HER2-Negative, Axillary Lymph Node Negative Breast Cancer: A Real-World Comparison of Alberta Patients Treated 2008-2012.

Autor: Hannouf M; Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N2, Canada., Batra A; Department of Medical Oncology, Tom Baker Cancer Center, 1331 29 ST NW, Calgary, AB T2N 4N2, Canada.; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi 110029, India., Lupichuk S; Department of Medical Oncology, Tom Baker Cancer Center, 1331 29 ST NW, Calgary, AB T2N 4N2, Canada.

Publikováno v: Current oncology (Toronto, Ont.) [Curr Oncol] 2021 Mar 04; Vol. 28 (2), pp. 1137-1142. Date of Electronic Publication: 2021 Mar 04.